MAPT and Alzheimer disease: Lucey et al. (2023) administered suvorexant (which blocks the receptors for the wake promoting neurotransmitter, orexin) to healthy adults while monitoring CSF and found a 10% reduction in toxic soluble amyloid and tau species. These findings are driving an ongoing randomized clinical trial of suvorexant in AD patients (NCT04629547). Second, sleep is important for cognition in all people regardless of AD, and sleep pathology impairs attention, memory, and processing speed (Durmer, 2005; Alhola and Polo-Kantola, 2007; Csipo et al., 2021).